Please assess the completion status of the following clinical trial:

Trial Title: Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~\* Diagnosis of B-cell chronic lymphocytic leukemia (CLL)~- Early-stage, biologically high-risk disease defined by the following criteria:~* Rai stage 0-II (does not meet standard NCI-sponsored Working Group criteria for treatment)~* Clinical and phenotypic features manifested in the peripheral blood, including the following:~  * Minimum threshold peripheral blood lymphocyte count of \> 5,000/mm³~ * Small-to-moderate peripheral blood lymphocytes with ≤ 55% prolymphocytes~ * Monoclonality of B lymphocytes by immunophenotypic evaluation, demonstrating co-expression of CD19, CD5, and CD23 antigens, surface expression of CD20 and CD52, and B-cell monoclonal population defined by light-chain exclusions~* Poor prognosis demonstrated by ≥ 1 of the following high-risk parameters:~  * Unmutated human immunoglobulin variable region heavy chain (IgVH) gene and CD38 expression (≥ 30% cells positive on flow cytometry) OR unmutated IgVH ZAP-70 expression (≥ 20% cells positive on flow cytometry) = 11q- = 17p-~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Creatinine ≤ 1.5 times upper limit of normal (ULN)~* Total bilirubin ≤ 3.0 times ULN OR direct bilirubin ≤ 1.5 times ULN~* AST ≤ 3.0 times ULN (unless due to hemolysis or CLL)~* Hemoglobin ≥ 9.0 g/dL~* No New York Heart Association class III-IV heart disease~* No myocardial infarction within the past month~* No uncontrolled infection~* No active HIV infection~* No evidence of autoimmune hemolytic anemia, immune thrombocytopenia, or pure red blood cell aplasia~* No other active primary malignancy requiring treatment or limiting survival to less than 2 years~PRIOR CONCURRENT THERAPY:~* No prior treatment for CLL~* Prior corticosteroids allowed~* No prior radiotherapy~* More than 4 weeks since prior major surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alemtuzumab + Rituximab (Type: EXPERIMENTAL): Alemtuzumab 30mg Monday, Wednesday, and Friday x 5 weeks, Rituximab 375/mg/m2 IV weekly (Wednesday) x 4 weeks (weeks 2-5)

Based on this trial design, predict the completion outcome and termination type (if applicable).